About the Study: In this study, GLP-1 RA initiation was associated with lower mortality and cardiovascular events compared to SGLT2 inhibitor initiation, with greater absolute reductions in SMI. Benefits were evident within 1 year, consistent across SMI subgroups, and driven by semaglutide and tirzepatide. Prospective randomized trials are warranted.
Corresponding Author: Roger S. McIntyre, MD, Brain and Cognition Discovery Foundation, 77 Bloor St W, Ste 617, Toronto, ON M5S 1M2, Canada ( roger.mcintyre@bcdf.org ).
10.1001/jamapsychiatry.2026.2574
To access the embargoed study: Visit our JAMA Network Media Center at this link https://media.jamanetwork.com/
Link to the article in your story
We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)
Editor's Note: Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
JAMA Psychiatry
Glucagon-Like Peptide 1 Receptor Agonists, Mortality, and Cardiovascular Outcomes in Serious Mental Illness